|
FOR US RESIDENTS ONLY
|
Chronic Myeloid Leukemia (CML)
Blood Level Testing
Oral therapies are becoming more common in oncology--and it has only recently begun to be recognized that adherence to therapy may be an issue with oral oncology drugs.
One of the first large studies of adherence to oral cancer medication showed that:
- On average, patients (N = 4043) took only 75% of their prescribed oral cancer therapy over the 14-month study period1
- Patients were on therapy an average of only 62% of the study period (266 days out of 14 months)1
- Adherence began to decline after 4 months of treatment1
In another study, it was shown that patients may overestimate their adherence to oral cancer therapies by a factor of 2 in discussions with their physicians.2
Blood Level Testing to Help Identify Nonadherence
To help optimize treatment outcomes for Ph+ CML patients, CML Alliance™ offers clinicians state-of-the-art blood level testing, a form of therapeutic drug monitoring, to help identify suboptimal response due to nonadherence.
- Blood level testing may offer a positive way for healthcare professionals to initiate an “evidence-based” discussion of the importance of adherence with patients
- Blood level testing has been used successfully to identify suboptimal responses due to nonadherence in other life threatening disease states such as AIDS3
Other Potential Uses Of Blood Level Testing
- You suspect that the patient may be experiencing a drug-drug interaction
- The patient isn't responding to oral cancer therapy as well as you believe he or she should be
- The patient is experiencing side effects that are unusually severe for the dose of oral cancer therapy he or she is taking
Blood level testing offered through CML Alliance™ will be performed by a CLIA-certified clinical laboratory with significant expertise in blood level testing.
Testing will be provided at no cost to either professional or patient. To find out how to register for this program, click here.
- Tsang JP et al. J Clin Oncol. 2006;24. Abstract 6119
- Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652-661. [p 652 (abstract), li 15-16]
- Hugen PW, Burger DM, Aarnoutse RE, et al. Therapeutic drug monitoring of HIV protease inhibitors to assess noncompliance. Ther Drug Monit. 2002;24:579-587. [Abstract conclusion]
Testing services
offered through CML Alliance ™ partners
Use of this website is governed by the
Terms of Use
and
Privacy Statement
.
Copyright 2008 Novartis Pharmaceuticals Corporation. All Rights Reserved.
|